Core Insights - C Beite-U (688759) experienced a significant increase of 74.41% on its first trading day, with a turnover rate of 73.25% and a transaction volume of 1.107 billion yuan [2] - The stock's first-day margin trading saw a buy amount of 74.9658 million yuan, accounting for 6.77% of the total trading volume, with a latest margin balance of 60.908 million yuan, representing 4.23% of the circulating market value [2] - C Beite is a biopharmaceutical company focused on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to creating first-in-class drugs and addressing unmet clinical needs [2] Financial Performance - On its debut, C Beite-U recorded a net inflow of 413 million yuan from main funds, with large orders contributing 201 million yuan and extra-large orders adding 212 million yuan [2] - The first-day financing balance for C Beite-U was 60.908 million yuan, which is 4.23% of its circulating market value [2] Recent IPO Performance - The recent IPOs on the same day included C He Yuan-U (688765) with a 213.49% increase, C Yi Cai-U (688783) with a 198.72% increase, and Tai Kai Ying (920020) with a 188.53% increase, indicating a strong performance across multiple new listings [3]
C必贝特-U获融资净买入6090.80万元